Get the content you want anytime you want.

The Contagion® Healthcare Associated Infections (HAI) specialty page provides HAI-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Evaluation of Fidaxomicin vs Vancomycin in Early Targeted Therapy of <i>C diff</i>
Nimish Patel, PharmD, PhD, describes his study, which compared fidaxomicin with oral vancomycin in early targeted therapy of C diff.
Paradigm Shift in Treatment for ABSSSI
Yoav Golan, MD, discusses the paradigm shift occurring in treatment for ABSSSI and how to motivate clinicians to buy into new programs and protocols.
The Dangers of Overtreating Asymptomatic Bacteriuria
Barbara Wells Trautner, MD, PhD, explains how overtreating asymptomatic bacteriuria can lead to antibiotic resistance or incorrect diagnoses.
Are Rapid Diagnostics Replacing Prediction Scores?
Julie Ann Justo, PharmD, MS, BCPS-AQ ID, explains how rapid diagnostics interplay with prediction scores in antimicrobial stewardship programs.
Treatment Challenges Remain as ABSSSI Incidence Continues to Grow
Yoav Golan, MD, discusses trends in the incidence of acute bacterial skin and skin structure infections, standard protocols for treatment, and the challenges clinicians continue to face.
Alternatives to Fluoroquinolones: Thinking Outside of the Box
Barbara Wells Trautner, MD, PhD, discusses finding alternatives to fluoroquinolones and facilitating patient communication to improve outcomes.
ABSSSI: Standard Protocol of Admission and Treatment
Panelists share the typical presentation of an acute bacterial skin and skin structure infection patient in the emergency department and the standard protocol of IV antibiotics.
An Overview of ABSSSI
Peter L. Salgo, MD; Yoav Golan, MD; and Bruce M. Jones, PharmD, BCPS, identify the commonalities of ABSSSI, including the predominant pathogens, such as Staphylococcus aureus and Streptococcus, and gram-positive infections.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?